Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Rang in aandelen #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Aandeelprijs
$9.60
Laatst gesynchroniseerd: 2025-05-21
Marktkapitalisatie
$1.08B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel OptiNose, Inc. (OPTN)

Categorie

P/S-ratio voor OptiNose, Inc. (OPTN)
P/S-ratio op August 2026 TTM: 1.24
Volgens de meest recente financiële rapporten en aandelenkoers van OptiNose, Inc. is de huidige P/S-ratio (TTM) 1.24. Eind 2023 had het bedrijf een P/S-ratio van 30.55.
P/S-ratiohistoriek voor OptiNose, Inc. van 2015 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 1.24 42.85%
2024 0.87 -97.16%
2023 30.55 1,366.42%
2022 2.08 -88.74%
2021 18.51 -69.68%
2020 61.04 -63.50%
2019 167.24 -68.05%
2018 523.46 0.00%
2017 0.00 -100.00%
2016 16.31 -99.98%
2015 89.58K 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten